skip to main content
Global Search Configuration

Pfizer Inc.GlaxoSmithKline PLCAllergan PLC and Eli Lilly & Co. are among big pharma firms facing generic competition to blockbuster brands, while AbbVie Inc. and Roche have got biosimilar rivals to worry about.


New drug launches have increased over the past couple of years, but few have reached blockbuster status yet. Meanwhile, China’s increasing appetite (and willingness to pay) for therapeutic innovation was a positive for several big pharma companies in the first quarter. Scrip’s webinar takes a deep dive into the key issues and trends emerging from industry earnings calls.


Read also


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: